Dogwood Therapeutics (DWTX)
NASDAQ:DWTX
Top Page
Dogwood Therapeutics
(NASDAQ:DWTX)
Select Model
Select Model
Rating:46Neutral
Price Target:
$2.00
▼(-36.51% Downside)
Action:ReiteratedDate:04/01/26
The score is weighed down primarily by weak financial performance (widening losses and higher cash burn) and bearish technicals (price below key moving averages with negative MACD). Corporate events provide partial support via runway-extending financing and pipeline progress, but valuation signals are limited due to ongoing losses and no dividend.
Positive Factors
Clinical progress (HALT-CINP enrollment)
Crossing the 50% enrollment milestone materially lowers trial execution risk and preserves timing for a Q3 2026 readout. On-time data readout can de-risk the program, improve partner or investor interest, and enable a clear path to Phase 3 if results are positive.
Negative Factors
Widening losses
As a pre-revenue biotech, widening annual losses reflect ramping development spend without offsetting revenue. Persistent negative earnings increase reliance on external funding, raise dilution risk, and mean the company must demonstrate clear clinical success to justify continued investment.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical progress (HALT-CINP enrollment)
Crossing the 50% enrollment milestone materially lowers trial execution risk and preserves timing for a Q3 2026 readout. On-time data readout can de-risk the program, improve partner or investor interest, and enable a clear path to Phase 3 if results are positive.
Read all positive factors
Dogwood Therapeutics (DWTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$70.48M
Dividend YieldN/A
Average Volume (3M)1.54M
Price to Earnings (P/E)―
Beta (1Y)2.43
Revenue GrowthN/A
EPS Growth-295.27%
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.26
Shares Outstanding33,401,554
10 Day Avg. Volume77,367
30 Day Avg. Volume1,536,657
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.46
Price to Sales (P/S)0.00
P/FCF Ratio-2.19
Enterprise Value/Market Cap-0.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit135.00
Enterprise Value/Ebitda0.08
Forecast
1Y Price Target
$13.50Price Target Upside328.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.98
Revenue Forecast (FY)N/A
Dogwood Therapeutics Business Overview & Revenue Model
Company Description
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IM...
How the Company Makes Money
null...
Dogwood Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -12.18K | 0.00 | 0.00 | 0.00 |
| EBITDA | -27.97M | -12.25M | -5.45M | -12.32M | -15.64M |
| Net Income | -34.26M | -12.35M | -5.30M | -12.25M | -15.96M |
Balance Sheet | |||||
| Total Assets | 90.17M | 94.31M | 4.17M | 8.37M | 15.78M |
| Cash, Cash Equivalents and Short-Term Investments | 6.52M | 14.85M | 3.32M | 7.03M | 14.01M |
| Total Debt | 162.60K | 15.59M | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 15.27M | 30.03M | 358.55K | 1.04M | 1.28M |
| Stockholders Equity | 74.90M | 64.28M | 3.81M | 7.33M | 14.50M |
Cash Flow | |||||
| Free Cash Flow | -15.62M | -8.79M | -4.87M | -11.47M | -15.69M |
| Operating Cash Flow | -15.62M | -8.79M | -4.87M | -11.47M | -15.69M |
| Investing Cash Flow | 0.00 | 3.76M | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 7.28M | 16.70M | 1.16M | 4.49M | -97.60K |
Dogwood Therapeutics Technical Analysis
Negative
3.15
Price Trends
2.84
Negative
3.97
Negative
4.61
Negative
Market Momentum
-0.27
Positive
37.75
Neutral
26.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DWTX, the sentiment is Negative. The current price of 3.15 is above the 20-day moving average (MA) of 2.64, above the 50-day MA of 2.84, and below the 200-day MA of 4.61, indicating a bearish trend. The MACD of -0.27 indicates Positive momentum. The RSI at 37.75 is Neutral, neither overbought nor oversold. The STOCH value of 26.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DWTX.
Dogwood Therapeutics Risk Analysis
Dogwood Therapeutics disclosed 67 risk factors in its most recent earnings report. Dogwood Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Dogwood Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $10.51M | -0.47 | -291.07% | ― | ― | 61.10% | |
46 Neutral | $70.48M | -3.99 | -56.64% | ― | ― | -295.27% | |
46 Neutral | $41.58M | -0.71 | -80.00% | ― | ― | 9.63% | |
44 Neutral | $22.01M | -1.88 | >-0.01% | ― | -12.99% | -13.67% | |
44 Neutral | $7.08M | ― | -420.31% | ― | 1.70% | -111.67% | |
41 Neutral | $8.24M | -0.31 | -97.58% | ― | -46.88% | 34.83% |
* Healthcare Sector Average
DWTX
Dogwood Therapeutics
2.11
-1.94
-47.90%
MRKR
Marker Therapeutics
1.32
0.31
30.69%
BRTX
BioRestorative Therapies
0.28
-1.42
-83.65%
SNSE
Sensei Biotherapeutics
31.02
25.02
417.00%
BOLT
Bolt Biotherapeutics
4.29
-2.74
-38.98%
ACXP
Acurx Pharmaceuticals
3.68
-2.88
-43.90%
Dogwood Therapeutics Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Dogwood Therapeutics Highlights Pipeline Progress and Extended Runway
Positive
Mar 26, 2026
On March 26, 2026, Dogwood Therapeutics issued a first-quarter shareholder letter detailing significant progress across its clinical pipeline and financing. The company highlighted enrollment of 145 patients in its Phase 2b HALT-CINP study of Haln...
Private Placements and FinancingShareholder Meetings
Dogwood Therapeutics Shareholders Approve Warrant Exercise Proposal
Positive
Mar 12, 2026
On March 11, 2026, Dogwood Therapeutics held a special meeting at which shareholders representing 88.03% of the company’s voting power were present, satisfying quorum requirements and underscoring strong investor engagement. At this meeting,...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Dogwood Therapeutics outlines 2026 plans for pain pipeline
Positive
Jan 20, 2026
In a January 20, 2026 shareholder letter, Dogwood Therapeutics reported that during 2025 it advanced its non-opioid pain and neuropathy pipeline by recruiting over 100 patients into its Phase 2b HALT-CINP study of Halneuron, securing a royalty-fre...
Business Operations and StrategyPrivate Placements and Financing
Dogwood Therapeutics Raises Capital via Registered Direct Financing
Positive
Jan 13, 2026
On January 11, 2026, Dogwood Therapeutics entered into a securities purchase agreement with a single institutional investor for a financing structure combining a registered direct offering and a concurrent private placement, issuing 2,338,948 shar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.